Related Experiment Videos
[Hip arthroplasty and thromboembolic complications].
H M Le Guyader1, Y Perramant, D Tepaut
1Service d'orthopédie, Centre hospitalier régional et universitaire de Brest.
Agressologie: Revue Internationale De Physio-Biologie Et De Pharmacologie Appliquees Aux Effets De L'Agression
|March 1, 1990
Summary
Standard dose heparin for 12 days reduced thromboembolic complications by 4.6% post-hip surgery. Adapted doses for 21 days lowered rates to 1.2%, confirming heparin
Area of Science:
- Orthopedic surgery
- Thromboembolic complication prevention
- Pharmacological prophylaxis
Context:
- The Orthopedic Department of Centre hospitalo-universitaire de Brest evaluated thromboembolic complication prevention strategies.
- Two distinct protocols involving subcutaneous heparin were compared over different time periods.
- Diagnostic methods evolved from isotopic to X-ray phlebography alongside lung scans.
Purpose:
- To assess the efficacy of different subcutaneous heparin regimens in preventing post-operative thromboembolic complications.
- To compare the outcomes of standard-dose, short-duration heparin versus adapted-dose, longer-duration heparin.
- To evaluate the impact of diagnostic method changes on complication assessment.
Summary:
- A 12-day standard-dose subcutaneous heparin protocol (1974-1984, 1287 cases) resulted in a 4.6% thromboembolic complication rate.
- A 21-day adapted-dose subcutaneous heparin protocol (1986-1987, 391 cases) reduced the complication rate to 1.2%.
- Heparin demonstrated effectiveness in preventing complications after total hip replacement, but less so after knee arthroplasty.
Impact:
- The findings support the use of adjusted-dose, extended-duration heparin for improved thromboembolic complication prevention in orthopedic surgery.
- Highlights the need for tailored prophylactic strategies, particularly noting differential outcomes in hip versus knee arthroplasty.
- Contributes to evidence-based guidelines for perioperative anticoagulation in joint replacement surgery.